Who Optimizes SG&A Costs Better? AstraZeneca PLC or Dynavax Technologies Corporation

Optimizing SG&A: AstraZeneca vs. Dynavax

In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for profitability. Over the past decade, AstraZeneca PLC and Dynavax Technologies Corporation have shown contrasting approaches. AstraZeneca, a global leader, has consistently maintained high SG&A expenses, peaking at approximately $18 billion in 2022. This reflects its expansive operations and robust marketing strategies. In contrast, Dynavax, a smaller biotech firm, has kept its SG&A costs significantly lower, with a peak of around $153 million in 2023. This lean approach highlights its focus on innovation and niche markets. Despite the vast difference in scale, both companies have optimized their SG&A relative to their operational models. AstraZeneca's expenses have grown by about 35% since 2014, while Dynavax's have surged by over 760%, indicating aggressive expansion. This data underscores the diverse strategies in managing operational costs within the pharmaceutical industry.